Nuvalent Insider Trades: 4k Shares Sold at $77-79 via 10b5-1 Plan
Rhea-AI Filing Summary
Form 4 Overview – Nuvalent, Inc. (NUVL)
On 06/26/2025, Chief Development Officer Darlene Noci reported a series of option exercises and related open-market sales under a pre-arranged Rule 10b5-1 trading plan dated 11/18/2024.
- Option exercise: 4,000 Class A common shares were acquired via option exercise at an exercise price of $27.85 per share.
- Dispositions: The exact 4,000 shares were immediately sold in three blocks: 85 sh at a weighted average $77.38, 3,609 sh at $78.70, and 306 sh at $79.15. Aggregate proceeds approximate $311 k, implying a spread of roughly $50 per share over the exercise price.
- Post-transaction holdings: Noci’s direct ownership declined from 52,034 to 48,034 shares (-7.7%). She retains 138,329 stock options expiring 01/06/2033.
No other equity classes or derivative instruments were reported. All transactions were effected under a 10b5-1 plan, suggesting routine portfolio management rather than discretionary selling.
Positive
- None.
Negative
- Insider sale of 4,000 shares (≈$311 k) reduces direct ownership by 7.7%, which can be perceived as a slight negative signal, even though executed under a 10b5-1 plan.
Insights
TL;DR – Modest insider sale (4k sh) under 10b5-1; limited signal value.
The exercise-and-sale sequence is economically neutral to the share count yet trims the insider’s direct stake by 4,000 shares, worth roughly $0.3 million. Because the sale represents under 8% of her holdings and is covered by a 10b5-1 plan adopted months earlier, the informational content is muted. Investors typically view insider sales as a mild negative, but the structured nature, small size, and continued sizeable ownership (>48 k shares plus 138 k options) reduce concern. Strategically, no implications for Nuvalent’s operations or capital structure arise. Impact on valuation or sentiment should be minimal.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 4,000 | $27.85 | $111K |
| Sale | Class A Common Stock | 85 | $77.38 | $7K |
| Sale | Class A Common Stock | 3,609 | $78.70 | $284K |
| Sale | Class A Common Stock | 306 | $79.15 | $24K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.04 to $77.61, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.08 to $79.07, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.08 to $79.33, inclusive. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
